Cyclacel Pharmaceuticals, Inc.

Equities

CYCC

US23254L8019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.65 ^USD	+7.14%		+2.48%	-38.20%

Jun. 26	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Jun. 26	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT

Nicholas Bacopoulos Intends to Retire from Cyclacel Pharmaceuticals, Inc.'s Board of Directors

July 06, 2016 at 05:01 pm EDT

Cyclacel Pharmaceuticals, Inc. announced that Nicholas Bacopoulos notified the company that he intends to retire for personal reasons from the company's board of directors effective from July 1, 2016.

Latest news about Cyclacel Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Softer Late Afternoon	Jun. 26	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	Jun. 26	MT
Cyclacel Receives Notice of European Patent Grant for Plogosertib; Shares Rise	Jun. 26	MT
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions	Jun. 26	CI
Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib?s Potential as Precision Medicine for Cancer	Jun. 03	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000	May. 14	MT
Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding	May. 01	CI
Top Midday Gainers	Apr. 30	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting	Apr. 30	MT
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8.000001 million in funding	Apr. 29	CI
Cyclacel Pharmaceuticals Withdraws Securities Offering SEC Filing	Apr. 29	DJ
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer	Apr. 01	CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024	Mar. 19
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000	Mar. 19	MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Cyclacel Pharmaceuticals, Inc. Announces Board Changes	Jan. 30	CI
Cyclacel Pharmaceuticals, Inc. Announces Executive Changes	Jan. 30	CI
Top Premarket Gainers	Jan. 08	MT
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $0.026374 million in funding	Dec. 21	CI
North American Morning Briefing : S&P 500 Futures -2-	Dec. 20	DJ
Brookline Capital Downgrades Cyclacel Pharmaceuticals to Hold From Buy	Dec. 19	MT
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions	Dec. 18	CI

Chart Cyclacel Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cyclacel Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.65 USD

Average target price

11 USD

Spread / Average Target

+566.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYCLACEL PHARMACEUTICALS, INC.	-38.20%	2.41M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs